Adding other antihypertensive drugs may lower the risk of heart failure in high risk patients receiving doxazosin therapy for hypertension.
As previously reported from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial, high-risk patients initially treated with doxazosin appear to have twice the risk for heart failure than those treated with chlorthalidone.
Barry R. Davis, MD, PhD, at the University of Texas School of Public Health, in Houston, United States, and colleagues studied the effect of adding another, open-label antihypertensive drug on the relative risk of heart failure among high risk hypertensive patients treated with doxazosin.
Patients at 623 sites in the United States and Canada were enrolled in the randomized, double-blind, active-controlled clinical trial. All patients were at least 55 years of age and had at least one additional risk factor for cardiovascular disease. They received either chlorthalidone (12.5 to 25 mg/d) or doxazosin (2 to 8 mg/d) for a planned follow-up of four to eight years.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!